Why Innovation Matters in First-Line HER2-Positive Gastroesophageal Adenocarcinoma

In oncology, progress can sometimes be tangible, yet in certain areas, the urgency to push further is undeniable. From my perspective, first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) is one such area. Here, early treatment decisions don’t just influence the course of care, they can shape the entire disease trajectory and potentially impact survival.

GEA, which includes cancers of the stomach, gastroesophageal junction, and esophagus, continues to carry a poor prognosis when diagnosed at advanced stages. Approximately 20 percent of patients have HER2+ tumors, a subgroup of this type of cancer where targeted therapies have helped move care forward. While these advances have helped improve outcomes for patients, sustaining benefit over time remains a challenge.^1,2,3,4

The importance of getting first-line treatment right

For patients with metastatic GEA, first-line therapy represents a critical opportunity to translate early advances into lasting benefit. For more than a decade, combining chemotherapy with HER2-targeted therapy established a new standard of care and marked a clear advance for patients. More recently, biomarker-driven approaches have continued to refine treatment for some patients.^2,3

Even with these advances, outcomes for many patients remain limited in duration. Too often, initial responses are followed by disease progression within two years. This reflects a broader reality in oncology, where the full impact of early progress depends on its ability to be sustained over time.^3,4

Why durability is meaningful for patient outcomes

HER2 is a well-validated therapeutic target, yet HER2+ GEA is biologically complex. Tumor heterogeneity, changes in HER2 expression over time, and emerging resistance all contribute to the difficulty of sustaining responses. These factors help explain why early benefit does not always translate into sustained disease control.^3,5

Addressing this complexity requires more than simply building on what exists today. It requires continued scientific focus and a willingness to rethink how therapies are designed and evaluated, with durability and long-term impact as central goals rather than secondary considerations.³

Progress in cancer care rarely happens all at once. It is built step by step, through persistent research, deeper understanding of disease biology, and a clear focus on what matters most to patients. In HER2+ GEA, meaningful progress has been made, and the opportunity to build on this foundation is substantial.

At Jazz, our oncology research is guided by a commitment to patients facing serious diseases and evolving treatment landscapes. By continuing to focus on first-line innovation and the need for improved survival outcomes, we believe there is an opportunity to change expectations for patients and families affected by this challenging disease. We are proud to have presented data at the ASCO GI 2026 meeting that showed improvements over current standards of care for patients – marking a potential shift in how patients will be treated with first-line therapy. The commitment we have to advancing new treatment for patients drives our work today and informs how we will continue to advance progress for patients in the years ahead.

References:

1. Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update WorldJGastroenterol. 2016;22(19):4619-4625
2. Van Custem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-484.
3. Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. CancerTreatRev. 2021;99:102249.
4. Battaglin F, et al. Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions. Cancer Cell International. 2018;18(99).
5. Gambardella, V at al. Precision medicine to treat advanced gastroesophageal adenocarcinoma: a work in progress. Journal of clinical medicine. 2020; 9(9), 3049.